A practical down-to-earth manual on the whole range of long-term conditions has been written for UK general practice nurses by experts in their field. The book provides a quick way for new practice nurses to learn the basics about long-term conditions and will also be useful to the wider primary healthcare team.
The new OneTouch Reveal® mobile app is now available in the UK and Ireland. It includes innovative features including blood sugar and activity timelines transformed into quick visual snapshots which allow people with diabetes to see their results, identify trends and get on with their daily life.
Leading clinicians and researchers in the USA have proposed a new model for the development of type 2 diabetes which they call ‘Dysglycaemia-based chronic disease’ or DBCD. The four stages of type 2 diabetes have been presented in a recent position statement by the American Association of Clinical Endocrinologists and the American College of Endocrinology.
A new blueprint for diabetes care has been published by NHS England in a bid to improve and reduce variation of care.
Glycated haemoglobin – HbA1C, or A1C as it is now being called – should be used to diagnose diabetes, according to a recent recommendation from an international expert committee appointed by the American Diabetes Association, the International Diabetes Federation and the European Association for the Study of Diabetes. We explore the basis for this recommendation, and look at why HbA1C would provide a more accurate measure for diagnosing diabetes than glucose tests and what the change would mean in clinical practice.
The new NICE Quality Standard provides a valuable framework for healthcare professionals involved in pre- and post-natal care. The new QS covers the management of diabetes and its complications in women who are planning a pregnancy and those already pregnant.
NICE has published a new diabetes quality standard for adults featuring seven new and updated statements covering type 2 diabetes prevention, structured education programmes, care and treatment, and prevention and management of foot problems. The new quality standard updates the 2011 version.
Dapagliflozin is now recommended by NICE as part of triple therapy with metformin and a sulfonylurea when two drugs for type 2 diabetes are not providing glycaemic control.